2026年3月12日 ，微创神经外科设备公司 Monteris Medical 宣布完成 2800万美元（约2亿元人民币）E轮融资 。公司同时披露，其已重新安排债务结 构，并与投资机构 Trinity Capital 建立 3500万美元（约2.5亿元人民币）新的信贷额度 。 本轮资金将主要用于扩大公司在美国的商业化布局，同时推动技术研发、临床研究以及国际市场拓展。 在 微创神经外科技术 这一细分领域，资本的持续投入反映出一个趋势：以影像导航和能量治疗为核心的新一代神经外科设备，正在成为全球医疗技术创新 的重要方向之一。 # 一家专注微创神经外科的设备公司 该系统通过 磁共振成像（MRI）引导下的激光消融技术（LITT） ，实现对脑部病灶的精准热消融治疗。其主要应用场景包括： 在手术过程中，医生通过影像导航将激光导管置入病灶区域，再利用激光产生的热能进行精准消融，同时通过MRI实时监测组织温度变化，从而减少对正常脑组织 的损伤。 与传统开颅手术相比，这类技术的核心优势在于： 因此在部分脑肿瘤和难治性癫痫治疗中逐渐获得应用。 # MRI引导激光消融：神经外科的一条技术路径 在神经外科领域，近年来微创技术的发展主 ...

Summary of EDAP TMS FY Conference Call Company Overview - **Company**: EDAP TMS (NasdaqGM:EDAP) - **Focus**: Global leader in therapeutic ultrasound, specifically for the treatment of cancer and benign diseases, with a strong emphasis on prostate cancer treatment using Focal One technology [2][3] Industry Insights - **Market Opportunity**: - Nearly 1.5 million newly diagnosed prostate cancer cases annually, projected to double to 2.9 million by 2040 [2] - Significant unmet needs in prostate cancer treatment, particularly for patients with intermediate risk [3] Core Product Insights - **Focal One Technology**: - Robotic High-Intensity Focused Ultrasound (HIFU) as a first-line treatment for prostate cancer, addressing a gap between active surveillance and radical treatments [3][4] - Focal One is positioned as a desirable treatment option, already included in guidelines for salvage therapy [4] Clinical Evidence - **Efficacy and Outcomes**: - Focal One demonstrates comparable cancer control to traditional treatments (surgery and radiation) while offering superior functional outcomes, such as preservation of urinary continence and erectile function [10][11] - Landmark studies (HIFI and FARP) show that HIFU has lower complication rates and better functional outcomes compared to surgery [10][11][12] Market Dynamics - **Growth Trends**: - HIFU is experiencing exponential growth, while traditional surgery and radiation therapies are stagnating or declining [6] - The company reported a 52% growth in Focal One installations and a 44% increase in procedures from 2021 to 2025 [19] Reimbursement Landscape - **Payment Mechanisms**: - New Medicare payment mechanisms have increased reimbursement rates for HIFU, making it competitive with traditional surgical payments [12][13] Adoption and Expansion - **Installed Base**: - As of December 31, 2025, 87 Focal One systems installed across 42 academic and 45 community hospitals in the U.S., including top-rated cancer hospitals [13][14] - Growing presence in Europe with 41 systems and 254 treatment sites [16] Future Opportunities - **Additional Markets**: - Potential expansion into treating Benign Prostatic Hyperplasia (BPH) and endometriosis, with significant market sizes identified [16][18] - The U.S. endometriosis market includes 66.5 million diagnosed women, with a focus on providing non-invasive treatment options [18] Competitive Landscape - **Comparison with Other Therapies**: - Discussion on Aquablation therapy for BPH, highlighting concerns about its efficacy and safety compared to HIFU [29][31] Management and Strategy - **Leadership Team**: - Proven management team with experience from leading med tech companies, positioning EDAP for continued growth and innovation in the therapeutic ultrasound market [20] Conclusion - **Outlook**: - EDAP TMS is well-positioned for growth in both men's and women's health markets, with a strong clinical evidence base and favorable reimbursement landscape supporting its innovative HIFU technology [20]

Summary of Pulse Biosciences FY Conference Call Company Overview - **Company**: Pulse Biosciences (NasdaqCM:PLSE) - **Industry**: Medical Devices, specifically focusing on electrophysiology (EP) and atrial fibrillation (AF) treatment Key Points and Arguments Clinical Data and Product Efficacy - Pulse Biosciences presented data on the NS 360 catheter, achieving 100% efficacy in rhythm control at 6 months and 96% at 12 months, with 90% freedom from all atrial arrhythmias at 12 months [4][5][6] - The company attributes its success to the use of nanosecond pulsed field ablation (PFA), which allows for a more efficient energy delivery and a contiguous lesion creation, leading to deeper and higher quality lesions compared to traditional methods [6][7][10] - The total energy delivered by Pulse's system is lower than that of competitors, yet it achieves better outcomes due to the efficiency of energy penetration into tissue [10][11][12] Integration with Mapping Systems - The integration of mapping systems in the EFS study was noted as suboptimal, but improvements are expected in future studies with higher fidelity registration [13][19][20] - The company anticipates that better integration with mapping systems will enhance procedural efficiency and potentially improve outcomes, although achieving higher efficacy than 96% may be challenging [20][21] IDE Study and Enrollment - Pulse Biosciences has received IDE approval for a study involving 155 patients, targeting paroxysmal AF, with enrollment expected to begin in Q2 2026 [23][24] - The study is designed to be efficient, with the potential for multiple patients to be enrolled per site per day, which is expected to accelerate the enrollment process [25][30] Strategic Direction and Market Position - The company is focusing on the EP market, which is seen as highly attractive due to its growth potential [35][36] - Pulse Biosciences plans to pursue partnerships rather than building a complete organization independently, as this is viewed as a more efficient strategy to leverage their disruptive technology [37][38] - The company is positioned to combine its unique energy technology with mapping systems to capture significant market share in the coming years [38][39] Financial Outlook and Cash Management - As of the end of 2025, Pulse Biosciences had $80 million in cash, with additional funding options available through a $60 million ATM and a $200 million shelf registration [45] - The company expects an increase in cash burn throughout 2026, primarily due to the costs associated with the IDE studies [47][48] Conclusion - Pulse Biosciences is poised for significant advancements in the EP market with its innovative catheter technology and strong clinical data. The focus on strategic partnerships and efficient enrollment in clinical studies is expected to drive growth and enhance shareholder value moving forward [41][42][46]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $3.1 million, a 62% increase from $1.9 million in Q4 2024, driven by the U.S. launch of CGuard Prime and increased international market penetration [10] - U.S. revenue for Q4 was $866,000, representing a 74% sequential growth compared to Q3 [10] - International revenue for Q4 was $2.3 million, reflecting a 17% growth compared to $1.9 million in Q4 2024 [10] - Gross profit for Q4 2025 was $1.2 million, or 37.5% of revenue, up from $469,000 or 24.1% of revenue in Q4 2024, primarily due to a favorable shift in revenue mix towards U.S. sales [11] - Net loss for Q4 2025 was $11.8 million, or $0.14 per share, compared to a net loss of $9.2 million or $0.19 per share in Q4 2024 [13] Business Line Data and Key Metrics Changes - The CGuard Prime stent platform has been launched in the U.S., with over 500 cases completed and approvals gained in prominent Integrated Delivery Networks (IDNs) [6] - The company has built a U.S. commercial team of over 30 people, focusing on operational expansion and increasing manufacturing capacity [5] Market Data and Key Metrics Changes - The company is focusing on expanding its market presence in the U.S. and international markets, with a strategy to dominate the carotid stenting space [4] - The anticipated FDA approval for TCAR indications is expected to boost market opportunities significantly [8] Company Strategy and Development Direction - The company aims to achieve market leadership through a stent-first strategy, focusing on operational excellence and customer support [4] - Plans include expanding the clinical pipeline and advancing indications for CGuard, with multiple programs and studies underway [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of U.S. sales and anticipates continued progress in 2026, with revenue expected to be between $13 million and $15 million, reflecting a growth of approximately 45%-65% over 2025 [15] - The company is committed to continuous improvement and exceeding customer expectations, with plans to introduce enhancements to the delivery system in Q4 2026 [26] Other Important Information - Cash and cash equivalents and marketable securities were $54.2 million as of December 31, 2025, compared to $34.6 million at the end of the previous year [14] - The company has two remaining milestone-based tranches from a private placement, each providing gross proceeds of $17.9 million if fully exercised [14] Q&A Session Summary Question: Guidance for FY 2026 - Management expects moderate growth in OUS sales and acceleration in U.S. growth in the second half of 2026 due to anticipated TCAR indication and enhanced clinical performance [19][20] Question: Account Standpoint in the U.S. - Cases have been performed in roughly 80 centers, with over 200 centers in the pipeline for VAC and evaluation stages [23] Question: Next Generation Delivery System - The next generation delivery system is targeted for Q4 2026, with minor regulatory changes expected to go through a 30-day FDA review [26] Question: Timing for CGUARDIANS II Data - CGUARDIANS II data will be first revealed at the Charing Cross Symposium in April, likely as an interim cut [30] Question: Account Adoption and Productivity Metrics - A growing number of physicians are using CGuard as their everyday stent, with an average of 15-20 cases per physician per year [35]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 MicroPort NeuroScientic Corporation 微創腦科學有限公司 與傳統藥物支架相比，APOLLO Dream®支架系統能夠更加精準地控制藥物釋放 劑量，在保證療效的同時顯著降低進入人體的總藥物負荷。其藥物塗層採用可 降解材料，在完成藥物釋放後逐步降解，有助於降低遠期血栓形成風險。 – 1 – 突破性醫療器械認定旨在授予針對嚴重威脅生命或導致不可逆功能損害之疾 病而開發，且具有潛在顯著臨床優勢的創新醫療技術。APOLLO Dream®支架系 統是全球首個獲得該項認定的神經介入領域球囊擴張、快速交換式藥物洗脫 支架，該認定標誌著： 未來，本集團將持續推進APOLLO Dream®支架系統的全球臨床研究及註冊進程， 進一步拓展本公司在神經介入創新治療領域的國際影響力，並為全球患者提 供更加先進的治療選擇。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號： ...

Group 1: Sales Team and Strategy - The company has expanded its sales team to over 200 members, focusing on both online and offline sales channels [2] - The company prioritizes both revenue and profit, viewing them as indicators of market share and profitability [2] - The company has a rich reserve of medical device products, including Class II and Class III devices [2] Group 2: Shareholder and Incentive Plans - The chairman currently has no plans to reduce his shareholding, and any future plans will comply with regulatory disclosure obligations [3] - The company has plans for stock incentives, but the specific timeline for implementation is uncertain [3] Group 3: Financial Position and Market Performance - The company is monitoring potential acquisition targets but has not identified any suitable candidates at this time [3] - The offline business model has a significantly higher net profit margin compared to the online model, and the company aims to enhance offline operations for stable profit contributions [3] - Sales performance during the promotional period in March was satisfactory and aligned with company expectations, with a focus on daily sales [3]

Investment Rating - The report maintains an investment rating of "Leading the Market" for the medical device industry, indicating that the industry index is expected to outperform the CSI 300 index by more than 5% [3][8]. Core Insights - The brain-computer interface (BCI) sector is included in the "14th Five-Year Plan" as one of the six future industries requiring proactive layout, signaling a period of intensive policy support and technological advancement [6]. - The first domestically approved invasive brain-computer interface medical device, developed by Borui Kang, has been launched, marking a significant breakthrough in clinical applications for patients with quadriplegia due to cervical spinal cord injuries [6]. - The capital market remains active, with Ladder Medical completing a strategic financing round of 500 million yuan, which will accelerate its clinical progress in the BCI field [6]. - The report suggests that the medical device industry is poised for multidimensional development driven by technological platformization, AI diagnostics, and consumer healthcare expansion, with a focus on high-quality growth and long-term investment opportunities [6]. Summary by Sections Policy Insights - The BCI technology is now recognized at the national strategic level, with key technological advancements in hardware, algorithms, and databases being prioritized for development [6]. Application Developments - Borui Kang's BCI device consists of several components, including an implanted brain-computer interface, electrodes, and software, which have shown significant improvements in hand function for patients during clinical trials [6]. Market Activity - Ladder Medical's recent financing round led by Alibaba and other investors highlights the ongoing interest and investment in the BCI sector, with plans for large-scale clinical trials in 2026 [6]. Investment Recommendations - The report emphasizes the potential for investment in the BCI industry, particularly in companies with advanced clinical progress and commercialization prospects, such as Aipeng Medical, Xiangyu Medical, and Kefu Medical [6].

Core Viewpoint - The appointment of Kevin A. Lobo to GE HealthCare's board is significant, indicating a strategic shift rather than just an experience supplement, as it brings a new perspective on surgical processes and device applications [4][7]. Group 1: Appointment Significance - Lobo, as the current CEO of Stryker, brings over 25 years of management experience in the medical device industry, particularly in orthopedic, neurological, and surgical operations [3][6]. - The appointment is not a typical independent director role; Lobo will actively participate in GE HealthCare's strategic discussions, indicating a deeper, ongoing influence on the company's direction [9][17]. Group 2: Industry Context - GE HealthCare and Stryker represent different paths in the medical device industry: GE focuses on imaging and diagnostic products, while Stryker emphasizes clinical treatment and surgical devices [8][16]. - The competition in the medical device sector is evolving from single products to a comprehensive approach to clinical pathways, with companies beginning to overlap in capabilities [16][17]. Group 3: Potential Collaboration - The relationship between GE HealthCare and Stryker may indicate a potential for collaboration, as both companies are exploring synergies in surgical processes, particularly with advancements in imaging technology and surgical execution [11][12]. - The integration of imaging, navigation, and surgical execution is becoming more cohesive, suggesting that different types of companies will increasingly collaborate within the same clinical workflows [13][14]. Group 4: Strategic Connections - The appointment reflects a trend where companies establish connections at the board level before entering formal collaborations, providing a flexible and low-cost approach to strategic alignment [16][18]. - This type of connection may not yield immediate business results but can influence how companies perceive the industry and define their positions within it [17][18].

Summary of Key Points from the Conference Call Industry Overview - The conference call discusses the **biomedical industry** in China, highlighting its elevation as a new pillar industry in the national development plan, particularly focusing on **biomanufacturing, brain-computer interfaces, high-end medical devices, and innovative drug development** [1][2]. Core Insights and Arguments - **Policy Direction**: The top-level design of the biomedical industry policy emphasizes two core directions: "strong innovation" and "benefiting people's livelihood." The industry is recognized for its economic importance and social function, with a focus on improving the healthcare system [2][3]. - **Medicare Adjustments**: In 2026, the per capita financial subsidy for Medicare is planned to increase by **24 yuan**, a slight decrease from the **30 yuan** increase in 2025, indicating a continued trend of increasing government subsidies despite a slight adjustment in growth rate [2]. - **Support for Innovative Drugs**: The 2025 Medicare drug list adjustment reflects strong support for "true innovation," with **40%** of the newly added **114 drugs** being first-class new drugs, and **50%** of these being biological products [5][6]. - **Renewal Rules**: The renewal rules for drugs in the Medicare directory show a stable support attitude towards high-value mature products, with **92%** of drugs renewing without price reductions [6]. - **Commercial Insurance Directory**: The first commercial insurance directory introduced in 2025 included **19 out of 141** reported drugs, focusing on high-innovation products and offering significant policy benefits [7][8]. - **Accelerating Domestic Drug Access**: Measures have been taken to accelerate the access of domestic innovative drugs to hospitals, including a requirement for medical institutions to hold drug committee meetings within **three months** of the Medicare directory release [9]. Additional Important Content - **Consolidation in Retail Pharmacy**: The retail pharmacy industry is expected to enter a phase of high-quality development and horizontal mergers starting in 2026, with policies encouraging pharmacies to execute equal outpatient insurance treatment as grassroots medical institutions [11]. - **IVD Sector Developments**: The IVD sector is seeing significant changes, including a focus on reducing the number of chargeable items and ensuring that AI-assisted diagnostics do not incur additional fees [17][18]. - **Medical Device Industry Trends**: The medical device industry is experiencing a slowdown in bidding procurement growth, with an expansion of centralized procurement covering about **30%** of the industry, particularly in county-level medical communities [19][20]. - **Medicare Payment Reform**: The upcoming **DRG/DIP 3.0** version is expected to provide more specific support for innovation, while a nationwide pilot for traditional Chinese medicine payment by disease will also be initiated [20][21]. - **Regulatory Changes**: New regulatory measures are being implemented to enhance the efficiency of Medicare fund clearing and to apply AI technology in regulatory processes [22]. This summary encapsulates the key points discussed in the conference call, providing insights into the current state and future direction of the biomedical industry in China.

Summary of the Conference Call for 蓝帆医疗 (Blue Sail Medical) Company Overview - **Company**: 蓝帆医疗 (Blue Sail Medical) - **Industry**: Medical Devices, specifically focusing on cardiovascular products and protective gloves Key Points Industry and Business Performance - **Cardiovascular Business**: Expected to turn profitable by 2025, with a focus on expanding hospital coverage to over 3,000 and achieving a million-level implant volume. Self-developed products are projected to account for 50% of sales, with gross margins potentially recovering to over 60% [2][4] - **Protective Gloves Business**: Anticipated to achieve stable profitability by Q1 2026, driven by geopolitical factors and raw material price increases. Prices for nitrile gloves are expected to rise by over $7 per box, and PVC gloves by $2-3 per box [2][7] - **Investment in Thailand**: A $200 million investment from Thailand aims to address energy cost issues by acquiring a local power plant and constructing a new facility, which will significantly reduce production costs [2][5] Financial Performance and Projections - **Historical Losses**: The company faced losses from 2021 to 2024, with amounts of 400 million, 300 million, 200 million, and 100 million respectively. Strategies to mitigate losses include expanding market access and increasing self-developed product sales [4][6] - **Future Profitability**: By 2025, the company expects to achieve profitability exceeding 100 million, with a gross margin recovery to 60% [4][6] Strategic Initiatives - **Forward Stockpiling Strategy**: The company has stockpiled low-cost nitrile latex to benefit from price increases expected in 2026, with inventory sufficient until May 2026 [2][7][11] - **International Expansion**: The cardiovascular business is expanding internationally, with an overseas sales team of over 200 people and projected overseas revenue exceeding 800 million RMB by 2025 [2][12] Challenges and Responses - **Energy Costs**: High energy costs have been a significant challenge. The investment from Thailand is expected to alleviate this issue by integrating energy supply and improving production efficiency [5][6] - **Market Dynamics**: The company is navigating a challenging market environment, including price fluctuations due to geopolitical tensions and tariff policies [4][5][18] Market Trends and Pricing - **Price Increases**: The company anticipates significant price increases in gloves due to raw material cost pressures and market dynamics, with nitrile gloves expected to see a price increase of $7 or more per box [7][22] - **Demand Resilience**: Despite price increases, demand for gloves remains strong, with inventory levels low and customers expected to replenish stock quickly [15][22] Future Outlook - **High-Quality Development Cycle**: The company is entering a new growth phase, benefiting from demographic trends and increasing disease prevalence. The cardiovascular sector is expected to grow at double-digit rates [4][30] - **Strategic Partnerships**: The company is focusing on strategic partnerships and investments to enhance its product offerings and market presence, particularly in the cardiovascular space [12][30] Conclusion - **Long-term Vision**: 蓝帆医疗 aims to become a respected global company in the medical field, leveraging its experience and strategic initiatives to navigate challenges and capitalize on growth opportunities [30][31]